16987298_1|16987298|21171|#section_info|0:0|Results showed that BP significantly induced Fas expression (from one to 41.3-fold vs. one to 7.7-fold in DBTRG-05MG and RG2 cells, respectively) but not Fas-L expression.|#main_body|GO:0014070|response to organic cyclic compound|#go_definition|IEP|GOA|Fas(246097)|#gene_synonym
##EndOfRet##
16987298_2|16987298|21748|#section_info|0:0|Both procaspase 9 and procaspase 3 were highly activated in DBTRG-05MG, DBTRG 8401 and RG2 cells after BP treatment.|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|IEP|GOA|Casp3(25402)|#gene_synonym
0.66	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_9|16987298|134|abstract|0:0|The apoptosis-associated proteins were dramatically increased and activated by BP in DBTRG-05MG cells and RG2 cells, but RG2 cells did not express p53 protein.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_3|16987298|21748|#section_info|0:0|Both procaspase 9 and procaspase 3 were highly activated in DBTRG-05MG, DBTRG 8401 and RG2 cells after BP treatment.|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|IEP|GOA|Casp9(58918)|#gene_synonym
0.66	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_9|16987298|134|abstract|0:0|The apoptosis-associated proteins were dramatically increased and activated by BP in DBTRG-05MG cells and RG2 cells, but RG2 cells did not express p53 protein.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_4|16987298|22035|#section_info|0:0|and the results showed that BP treatment increased the cleavage of caspase 3 protein to induce apoptosis of tumor cells in vivo (Fig. 3d). |#main_body|GO:0014070|response to organic cyclic compound|#go_definition|IEP|GOA|Casp3(25402)|#gene_synonym
0.74	16987298_192|16987298|26874|Results|0:0|The human GBM tumor tissues with BP treatment in vivo also displayed decreases in Ki-67 expression, and increases in cleaved caspase 3 protein expression and tumor cell apoptosis, relative to the control group in vivo, at day 10 after treatment (Fig. 5d).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_212|16987298|30940|Discussion|0:0|Our results are entirely consistent with an inhibition of tumor growth by BP due to cell-cycle arrest at the G0/G1 phase and the induction of apoptosis (Fig. 1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_232|16987298|32757|Discussion|0:0|2c shows that caspase 9 was increased) and sequentially results in procaspase 3 activation (Fig. 2d also shows that caspase 3 was increased) to proceed apoptosis processes.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_130|16987298|17277|Results|0:0|The TUNEL assay was used to verify the viability of detached cells and the results showed that the cells were in the process of apoptosis at 48 h (Figs 1a and b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_235|16987298|32757|Discussion|0:0|Fas is the death receptor responsible for signaling from the cell membrane, which triggers the activation of procaspase 8 (Fig. 2d shows that caspase 8 was increased) and subsequently, promotes procaspase 3 activation resulting in apoptosis.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_229|16987298|32757|Discussion|0:0|The immunoblotting results inferred the possible mechanisms of apoptosis induced by BP in GBM tumor cells.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_5|16987298|24595|#section_info|0:0|The immunohistochemistry results on day 16 after BP treatment showed a decrease in Ki-67 protein expression, an increase in cleaved caspase 3 protein expression and an increase in apoptosis in tumor cells relative to the control group in vivo (Fig. 4c);|#main_body|GO:0014070|response to organic cyclic compound|#go_definition|IEP|GOA|Mki67(291234)|#gene_synonym
0.86	16987298_192|16987298|26874|Results|0:0|The human GBM tumor tissues with BP treatment in vivo also displayed decreases in Ki-67 expression, and increases in cleaved caspase 3 protein expression and tumor cell apoptosis, relative to the control group in vivo, at day 10 after treatment (Fig. 5d).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_178|16987298|25796|Results|0:0|(c) Immunohistochemical staining and TUNEL assay were performed in rat brain tumor tissues (on day 16 after BP treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_203|16987298|28976|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors were immunohistochemically stained for the cell proliferation marker, Ki-67 (i and ii), cell apoptosis marker, caspase 3 (active form; iii and iv), and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_130|16987298|17277|Results|0:0|The TUNEL assay was used to verify the viability of detached cells and the results showed that the cells were in the process of apoptosis at 48 h (Figs 1a and b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_168|16987298|23426|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors, immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with cleaved caspase 3 (iii and iv) and DNA fragmentation of apoptosis cells with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_179|16987298|25796|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with caspase 3 (active form; iii and iv) and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_232|16987298|32757|Discussion|0:0|2c shows that caspase 9 was increased) and sequentially results in procaspase 3 activation (Fig. 2d also shows that caspase 3 was increased) to proceed apoptosis processes.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_167|16987298|23426|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were analyzed in GBM tumor tissues (at day 18 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_136|16987298|17643|Results|0:0|Flow cytometric analysis of DNA contents in the BP-treated (open bars) and control cells (black bars) revealed the proportions of cells at different cell-cycle stages after BP treatment for 6, 12 and 24 h. Each column represents the mean +- SD (*p < 0.05).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_202|16987298|28976|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were performed in human GBM tumor tissues (on day 10 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_212|16987298|30940|Discussion|0:0|Our results are entirely consistent with an inhibition of tumor growth by BP due to cell-cycle arrest at the G0/G1 phase and the induction of apoptosis (Fig. 1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_6|16987298|24595|#section_info|0:0|The immunohistochemistry results on day 16 after BP treatment showed a decrease in Ki-67 protein expression, an increase in cleaved caspase 3 protein expression and an increase in apoptosis in tumor cells relative to the control group in vivo (Fig. 4c);|#main_body|GO:0014070|response to organic cyclic compound|#go_definition|IEP|GOA|Casp3(25402)|#gene_synonym
0.86	16987298_192|16987298|26874|Results|0:0|The human GBM tumor tissues with BP treatment in vivo also displayed decreases in Ki-67 expression, and increases in cleaved caspase 3 protein expression and tumor cell apoptosis, relative to the control group in vivo, at day 10 after treatment (Fig. 5d).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_178|16987298|25796|Results|0:0|(c) Immunohistochemical staining and TUNEL assay were performed in rat brain tumor tissues (on day 16 after BP treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_203|16987298|28976|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors were immunohistochemically stained for the cell proliferation marker, Ki-67 (i and ii), cell apoptosis marker, caspase 3 (active form; iii and iv), and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_130|16987298|17277|Results|0:0|The TUNEL assay was used to verify the viability of detached cells and the results showed that the cells were in the process of apoptosis at 48 h (Figs 1a and b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_168|16987298|23426|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors, immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with cleaved caspase 3 (iii and iv) and DNA fragmentation of apoptosis cells with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_179|16987298|25796|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with caspase 3 (active form; iii and iv) and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_232|16987298|32757|Discussion|0:0|2c shows that caspase 9 was increased) and sequentially results in procaspase 3 activation (Fig. 2d also shows that caspase 3 was increased) to proceed apoptosis processes.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_167|16987298|23426|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were analyzed in GBM tumor tissues (at day 18 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_136|16987298|17643|Results|0:0|Flow cytometric analysis of DNA contents in the BP-treated (open bars) and control cells (black bars) revealed the proportions of cells at different cell-cycle stages after BP treatment for 6, 12 and 24 h. Each column represents the mean +- SD (*p < 0.05).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_202|16987298|28976|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were performed in human GBM tumor tissues (on day 10 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_212|16987298|30940|Discussion|0:0|Our results are entirely consistent with an inhibition of tumor growth by BP due to cell-cycle arrest at the G0/G1 phase and the induction of apoptosis (Fig. 1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_7|16987298|24595|#section_info|0:0|The immunohistochemistry results on day 16 after BP treatment showed a decrease in Ki-67 protein expression, an increase in cleaved caspase 3 protein expression and an increase in apoptosis in tumor cells relative to the control group in vivo (Fig. 4c);|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|IEP|GOA|Casp3(25402)|#gene_synonym
0.86	16987298_192|16987298|26874|Results|0:0|The human GBM tumor tissues with BP treatment in vivo also displayed decreases in Ki-67 expression, and increases in cleaved caspase 3 protein expression and tumor cell apoptosis, relative to the control group in vivo, at day 10 after treatment (Fig. 5d).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_178|16987298|25796|Results|0:0|(c) Immunohistochemical staining and TUNEL assay were performed in rat brain tumor tissues (on day 16 after BP treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_203|16987298|28976|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors were immunohistochemically stained for the cell proliferation marker, Ki-67 (i and ii), cell apoptosis marker, caspase 3 (active form; iii and iv), and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_130|16987298|17277|Results|0:0|The TUNEL assay was used to verify the viability of detached cells and the results showed that the cells were in the process of apoptosis at 48 h (Figs 1a and b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_168|16987298|23426|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors, immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with cleaved caspase 3 (iii and iv) and DNA fragmentation of apoptosis cells with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_179|16987298|25796|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with caspase 3 (active form; iii and iv) and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_232|16987298|32757|Discussion|0:0|2c shows that caspase 9 was increased) and sequentially results in procaspase 3 activation (Fig. 2d also shows that caspase 3 was increased) to proceed apoptosis processes.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_167|16987298|23426|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were analyzed in GBM tumor tissues (at day 18 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_136|16987298|17643|Results|0:0|Flow cytometric analysis of DNA contents in the BP-treated (open bars) and control cells (black bars) revealed the proportions of cells at different cell-cycle stages after BP treatment for 6, 12 and 24 h. Each column represents the mean +- SD (*p < 0.05).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_202|16987298|28976|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were performed in human GBM tumor tissues (on day 10 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_212|16987298|30940|Discussion|0:0|Our results are entirely consistent with an inhibition of tumor growth by BP due to cell-cycle arrest at the G0/G1 phase and the induction of apoptosis (Fig. 1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_8|16987298|24595|#section_info|0:0|The immunohistochemistry results on day 16 after BP treatment showed a decrease in Ki-67 protein expression, an increase in cleaved caspase 3 protein expression and an increase in apoptosis in tumor cells relative to the control group in vivo (Fig. 4c);|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|IEP|GOA|Mki67(291234)|#gene_synonym
0.86	16987298_192|16987298|26874|Results|0:0|The human GBM tumor tissues with BP treatment in vivo also displayed decreases in Ki-67 expression, and increases in cleaved caspase 3 protein expression and tumor cell apoptosis, relative to the control group in vivo, at day 10 after treatment (Fig. 5d).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_178|16987298|25796|Results|0:0|(c) Immunohistochemical staining and TUNEL assay were performed in rat brain tumor tissues (on day 16 after BP treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_147|16987298|19020|Results|0:0|However, levels of phosphorylated Rb proteins were decreased after BP treatment in DBTRG-05MG and DBTRG 8401 cells; in RG2 cells, the levels were decreased (0.8-fold) at 1.5 h, with phosphorylated proteins undetectable as early as 3 h after BP treatment (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	16987298_203|16987298|28976|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors were immunohistochemically stained for the cell proliferation marker, Ki-67 (i and ii), cell apoptosis marker, caspase 3 (active form; iii and iv), and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_130|16987298|17277|Results|0:0|The TUNEL assay was used to verify the viability of detached cells and the results showed that the cells were in the process of apoptosis at 48 h (Figs 1a and b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_168|16987298|23426|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors, immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with cleaved caspase 3 (iii and iv) and DNA fragmentation of apoptosis cells with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_179|16987298|25796|Results|0:0|Representative photographs of sections of the control group (i, iii and v) and BP-treated group (ii, iv and vi) GBM tumors immunohistochemically stained for cell proliferation marker with Ki-67 (i and ii), cell apoptosis marker with caspase 3 (active form; iii and iv) and DNA fragmentation of apoptosis cell with TUNEL staining (v and vi).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_232|16987298|32757|Discussion|0:0|2c shows that caspase 9 was increased) and sequentially results in procaspase 3 activation (Fig. 2d also shows that caspase 3 was increased) to proceed apoptosis processes.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	16987298_167|16987298|23426|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were analyzed in GBM tumor tissues (at day 18 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_136|16987298|17643|Results|0:0|Flow cytometric analysis of DNA contents in the BP-treated (open bars) and control cells (black bars) revealed the proportions of cells at different cell-cycle stages after BP treatment for 6, 12 and 24 h. Each column represents the mean +- SD (*p < 0.05).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_202|16987298|28976|Results|0:0|(d) Immunohistochemical staining and TUNEL assay were performed in human GBM tumor tissues (on day 10 after treatment).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_212|16987298|30940|Discussion|0:0|Our results are entirely consistent with an inhibition of tumor growth by BP due to cell-cycle arrest at the G0/G1 phase and the induction of apoptosis (Fig. 1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_9|16987298|34957|#section_info|0:0|However, although RG2 cells were impaired for p53 and p16, p27 and procaspase 9 expression induced by BP were increased in these cells.|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|NONE|GOA|Casp9(58918)|#gene_synonym
0.7	16987298_146|16987298|19020|Results|0:0|Furthermore, total p53 protein increased (twofold) at 12 h in DBTRG-05MG and DBTRG 8401 (twofold) increased at 3 h. In RG2 cells, the genes of p53 and p16 are impaired and exhibit homologous deletion, and these were undetectable in immunoblotting analysis.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	16987298_9|16987298|134|abstract|0:0|The apoptosis-associated proteins were dramatically increased and activated by BP in DBTRG-05MG cells and RG2 cells, but RG2 cells did not express p53 protein.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_150|16987298|19020|Results|0:0|The protein expression of cdk2, cdk4, cdk6, cyclin D1 and cyclin E in BP-treated GBM cells was also measured, and all five proteins were decreased in DBTRG-05MG and DBTRG 8401 cells; similar results for cdk2, cdk4, cdk6, cyclin D1, cyclin E and p21 were detected in RG2 cells after treatment with BP (Fig. 2b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_143|16987298|19020|Results|0:0|To investigate apoptotic pathways induced by BP treatment, phosphorylation of p53 and Rb proteins were first evaluated by immunoblotting.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_4|16987298|134|abstract|0:0|In vitro, GBM cells were treated with BP, and the effects of proliferation, cell cycle and apoptosis were determined.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
16987298_10|16987298|34957|#section_info|0:0|However, although RG2 cells were impaired for p53 and p16, p27 and procaspase 9 expression induced by BP were increased in these cells.|#main_body|GO:0071407|cellular response to organic cyclic compound|#go_definition|NONE|GOA|Cdkn1b(83571)|#gene_synonym
0.7	16987298_146|16987298|19020|Results|0:0|Furthermore, total p53 protein increased (twofold) at 12 h in DBTRG-05MG and DBTRG 8401 (twofold) increased at 3 h. In RG2 cells, the genes of p53 and p16 are impaired and exhibit homologous deletion, and these were undetectable in immunoblotting analysis.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	16987298_149|16987298|19020|Results|0:0|Levels of p16, p21, Bax and AIF protein in BP-treated GBM cells were therefore measured, and protein expression levels of all four proteins increased in DBTRG-05MG and DBTRG 8401 cells; similar results for p27, Bax and AIF were detected in RG2 cells after treatment with BP (Figs 2b and c).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	16987298_9|16987298|134|abstract|0:0|The apoptosis-associated proteins were dramatically increased and activated by BP in DBTRG-05MG cells and RG2 cells, but RG2 cells did not express p53 protein.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	16987298_150|16987298|19020|Results|0:0|The protein expression of cdk2, cdk4, cdk6, cyclin D1 and cyclin E in BP-treated GBM cells was also measured, and all five proteins were decreased in DBTRG-05MG and DBTRG 8401 cells; similar results for cdk2, cdk4, cdk6, cyclin D1, cyclin E and p21 were detected in RG2 cells after treatment with BP (Fig. 2b).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_143|16987298|19020|Results|0:0|To investigate apoptotic pathways induced by BP treatment, phosphorylation of p53 and Rb proteins were first evaluated by immunoblotting.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	16987298_152|16987298|20571|Results|0:0|Whole cell lysates (20 microg/lane) were analyzed with western blotting using specific antibodies to: (a) p53, phospho-p53 and phospho-RB; (b) p16, p21, p27, cdk2, cdk4, cdk6, cyclin D1 and cyclin E; (c) Bax, AIF and caspase 9; (d) Fas, Fas-L, caspase 8 and caspase 3.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_4|16987298|134|abstract|0:0|In vitro, GBM cells were treated with BP, and the effects of proliferation, cell cycle and apoptosis were determined.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	16987298_230|16987298|32757|Discussion|0:0|First, the p53-dependent apoptosis pathway was supposed because BP treatment could promote the phosphorylation of p53 in the DBTRG tumor cells and increase p53 expression, which peaked at 12 h (Fig. 2a).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
